Radiopharmaceuticals Market
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Radiopharmaceuticals</strong> <strong>Market</strong><br />
Shutting down these reactors, however, has propelled the installation of cyclotrons, which are also a<br />
feasible source for radioisotopes. Hence, sales of radiopharmaceuticals derived from cyclotrons will<br />
continue to increase, amassing more than US$ 6,500 million by the end of 2026.<br />
Surging Demand for Technetium-99 Radioisotope<br />
Production of radiopharmaceuticals can be classified into several key radioisotopes, the prominent ones<br />
include, fluorine-18, leutetium-177, gallium-68, gallium-67 and technetium-99. In 2016, sales of<br />
radiopharmaceuticals constituting technetium-99 amassed revenues worth over US$ 2,200 million,<br />
globally. By the end of 2026, fluorine-18 radioisotope will continue to account for 16% of global<br />
radiopharmaceuticals revenues. On the other hand, global radiopharmaceutical revenues accounted by<br />
leutetium-177, gallium-68 and gallium-67, respectively, will soar at more than 6% CAGR through 2026.<br />
North America – Dominant Region for Sales of <strong>Radiopharmaceuticals</strong><br />
Access to advanced medical facilities, highly-trained professionals and lucrative healthcare expenditure<br />
adds up to make North America the most dominant region in global radiopharmaceuticals market. North<br />
America’s radiopharmaceuticals revenues will grow at more than 6% CAGR, accounting for nearly 50% of<br />
global revenues by the end of 2026. Companies such as Positron Corporation, GE Healthcare,<br />
Mallinckrodt plc, Lantheus Holdings, Inc., and Nordion, Inc., are observed to be leading players in global<br />
radiopharmaceuticals market, and are all based across North America.<br />
©2015 Future <strong>Market</strong> Insights, All Rights Reserved 5
Change language